Merit Financial Group LLC cut its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 9.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,021 shares of the medical research company’s stock after selling 639 shares during the period. Merit Financial Group LLC’s holdings in Edwards Lifesciences were worth $498,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Edmond DE Rothschild Holding S.A. increased its holdings in Edwards Lifesciences by 11.9% in the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 22,126 shares of the medical research company’s stock valued at $1,651,000 after acquiring an additional 2,353 shares during the last quarter. Stonegate Investment Group LLC lifted its position in shares of Edwards Lifesciences by 22.3% in the first quarter. Stonegate Investment Group LLC now owns 13,118 shares of the medical research company’s stock worth $1,085,000 after buying an additional 2,392 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in Edwards Lifesciences by 72.6% during the first quarter. Vontobel Holding Ltd. now owns 729,156 shares of the medical research company’s stock valued at $60,323,000 after buying an additional 306,664 shares during the last quarter. Plimoth Trust Co. LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at approximately $316,000. Finally, Verus Capital Partners LLC increased its stake in Edwards Lifesciences by 220.0% in the 3rd quarter. Verus Capital Partners LLC now owns 4,330 shares of the medical research company’s stock worth $358,000 after acquiring an additional 2,977 shares during the last quarter. 79.78% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $90.78, for a total value of $2,664,393.00. Following the completion of the transaction, the director now directly owns 54,252 shares of the company’s stock, valued at approximately $4,924,996.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $90.78, for a total value of $2,664,393.00. Following the transaction, the director now owns 54,252 shares of the company’s stock, valued at approximately $4,924,996.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,635 shares of the stock in a transaction that occurred on Friday, May 5th. The shares were sold at an average price of $88.62, for a total transaction of $499,373.70. Following the sale, the vice president now directly owns 56,225 shares of the company’s stock, valued at approximately $4,982,659.50. The disclosure for this sale can be found here. Insiders sold a total of 231,031 shares of company stock worth $20,306,102 over the last 90 days. Company insiders own 1.29% of the company’s stock.
Analyst Upgrades and Downgrades
Edwards Lifesciences Stock Performance
Shares of Edwards Lifesciences stock opened at $90.26 on Friday. Edwards Lifesciences Co. has a 12 month low of $67.13 and a 12 month high of $107.92. The stock’s fifty day moving average price is $88.04 and its 200-day moving average price is $82.52. The firm has a market cap of $54.72 billion, a P/E ratio of 37.45, a P/E/G ratio of 5.14 and a beta of 1.03. The company has a current ratio of 3.01, a quick ratio of 2.17 and a debt-to-equity ratio of 0.10.
Edwards Lifesciences (NYSE:EW – Free Report) last posted its quarterly earnings results on Wednesday, April 26th. The medical research company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. Edwards Lifesciences had a net margin of 27.07% and a return on equity of 25.81%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.39 billion. During the same quarter in the previous year, the business posted $0.60 EPS. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.55 earnings per share for the current fiscal year.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Read More
- Five stocks we like better than Edwards Lifesciences
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
